Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy

Jan 15, 2021 | Magazine: Clinical Cancer Research

Diego Salas-Benito 1, Iñaki Eguren-Santamaria 1, Miguel F Sanmamed 2 3 4 5

Abstract

It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors. This study encourages further analysis of the role of senescent T cells in resistance to lung cancer immunotherapy.See related article by Ferrara et al., p. 492.

CITATION Clin Cancer Res. 2021 Jan 15;27(2):374-376. doi: 10.1158/1078-0432.CCR-20-3507. Epub 2020 Nov 13.

see publication in pubmed

Our authors

Imagen del Dr. Miguel Fernández de Sanmamed Gutiérrez, Investigador principal del grupo Onco-Inmunología Aplicada y Traslacional de la Clínica Universidad de Navarra

Dr. Miguel Fernández de Sanmamed Gutiérrez Curriculum

Researcher | Principal Investigator Applied and Translational Onco-Immunology Research Group